SK Bioscience Co Ltd
KRX:302440
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
35 850
60 100
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
SK Bioscience Co Ltd
Total Current Liabilities
SK Bioscience Co Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Current Liabilities
₩310.6B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Current Liabilities
₩4T
|
CAGR 3-Years
50%
|
CAGR 5-Years
34%
|
CAGR 10-Years
20%
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Current Liabilities
₩92B
|
CAGR 3-Years
22%
|
CAGR 5-Years
19%
|
CAGR 10-Years
28%
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Current Liabilities
₩256.4B
|
CAGR 3-Years
39%
|
CAGR 5-Years
68%
|
CAGR 10-Years
99%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Current Liabilities
₩51.5B
|
CAGR 3-Years
131%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Total Current Liabilities
₩11.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
SK Bioscience Co Ltd
Glance View
SK Bioscience Co Ltd., a remarkable enterprise carved out of the South Korean corporate landscape, operates at the dynamic intersection of biotechnology and pharmaceuticals. A part of the larger SK Group, one of Korea's leading conglomerates, the company was officially established in 2018 from SK Chemicals' life sciences division. Its primary focus is on developing and manufacturing vaccines, serving both public health needs locally and globally. The company has swiftly gained prominence for its role in the COVID-19 pandemic, particularly with the production of vaccines in collaboration with significant players such as AstraZeneca and Novavax. This strategic engagement loop has positioned SK Bioscience not only as a critical player in health crises management but also as a pivotal contributor to global health security. At the heart of SK Bioscience's business model is its ability to leverage cutting-edge research and robust manufacturing capabilities. The firm generates revenue through various channels, including product sales of its vaccines and other pharmaceuticals, contract manufacturing services, and partnerships with global entities, allowing it a diversified income stream. Its adeptness in innovation, underpinned by a strong R&D framework, ensures a steady development pipeline, supporting long-term growth ambitions. Through these strategic activities, SK Bioscience aligns itself with the SK Group’s broader commitment to social value and environmental, social, and governance (ESG) principles, fortifying its reputation as a company that not only seeks financial success but also endeavors to wield a positive global impact.
See Also
What is SK Bioscience Co Ltd's Total Current Liabilities?
Total Current Liabilities
310.6B
KRW
Based on the financial report for Dec 31, 2024, SK Bioscience Co Ltd's Total Current Liabilities amounts to 310.6B KRW.
What is SK Bioscience Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
47%
Over the last year, the Total Current Liabilities growth was 129%. The average annual Total Current Liabilities growth rates for SK Bioscience Co Ltd have been -12% over the past three years , 47% over the past five years .